Hoth Therapeutics (NASDAQ: HOTH) Reports its HT-KIT Novel Therapeutic Able to Block and Kill Cancer Cell Growth over 72 Hours, Orphan Drug Status Granted
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development, and ...
